Literature DB >> 25721204

Oncolytic viruses: focusing on the tumor microenvironment.

C R de Vries1, H L Kaufman1, E C Lattime1.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 25721204     DOI： 10.1038/cgt.2015.11

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN： 0929-1903            Impact factor:   5.987


× No keyword cloud information.
  24 in total

1.  Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer.

Authors:  James L Gulley; Christopher R Heery; Ravi A Madan; Beatriz A Walter; Maria J Merino; William L Dahut; Kwong-Yok Tsang; Jeffrey Schlom; Peter A Pinto
Journal:  Cancer Immunol Immunother       Date:  2013-07-09       Impact factor: 6.968

Review 2.  Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy.

Authors:  Takami Sato; Mizue Terai; Yutaka Tamura; Vitali Alexeev; Michael J Mastrangelo; Senthamil R Selvan
Journal:  Immunol Res       Date:  2011-12       Impact factor: 2.829

3.  Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment.

Authors:  Alexander M Lesokhin; Tobias M Hohl; Shigehisa Kitano; Czrina Cortez; Daniel Hirschhorn-Cymerman; Francesca Avogadri; Gabrielle A Rizzuto; John J Lazarus; Eric G Pamer; Alan N Houghton; Taha Merghoub; Jedd D Wolchok
Journal:  Cancer Res       Date:  2011-12-15       Impact factor: 12.701

4.  Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.

Authors:  Sung Yong Lee; Tae Heung Kang; Jayne Knoff; Zhuomin Huang; Ruey-Shyang Soong; Ronald D Alvarez; Chien-Fu Hung; T-C Wu
Journal:  Cancer Immunol Immunother       Date:  2013-04-25       Impact factor: 6.968

Review 5.  Going viral with cancer immunotherapy.

Authors:  Brian D Lichty; Caroline J Breitbach; David F Stojdl; John C Bell
Journal:  Nat Rev Cancer       Date:  2014-07-03       Impact factor: 60.716

6.  Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.

Authors:  Chie Kudo-Saito; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2004-02-01       Impact factor: 12.531

7.  Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.

Authors:  Jedd D Wolchok; James P Allison; Dmitriy Zamarin; Rikke B Holmgaard; Sumit K Subudhi; Joon Seok Park; Mena Mansour; Peter Palese; Taha Merghoub
Journal:  Sci Transl Med       Date:  2014-03-05       Impact factor: 17.956

8.  Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma.

Authors:  Howard L Kaufman; Dae Won Kim; Gail DeRaffele; Josephine Mitcham; Rob S Coffin; Seunghee Kim-Schulze
Journal:  Ann Surg Oncol       Date:  2010-03       Impact factor: 5.344

9.  The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Authors:  Kelley A Parato; Caroline J Breitbach; Fabrice Le Boeuf; Jiahu Wang; Chris Storbeck; Carolina Ilkow; Jean-Simon Diallo; Theresa Falls; Joseph Burns; Vanessa Garcia; Femina Kanji; Laura Evgin; Kang Hu; Francois Paradis; Shane Knowles; Tae-Ho Hwang; Barbara C Vanderhyden; Rebecca Auer; David H Kirn; John C Bell
Journal:  Mol Ther       Date:  2011-12-20       Impact factor: 11.454

10.  Oncolytic viruses as platform for multimodal cancer therapeutics: a promising land.

Authors:  Z S Guo; D L Bartlett
Journal:  Cancer Gene Ther       Date:  2014-07       Impact factor: 5.987
View more
  12 in total

1.  Therapeutic Immune Modulation against Solid Cancers with Intratumoral Poly-ICLC: A Pilot Trial.

Authors:  Chrisann Kyi; Vladimir Roudko; Rachel Sabado; Yvonne Saenger; William Loging; John Mandeli; Tin Htwe Thin; Deborah Lehrer; Michael Donovan; Marshall Posner; Krzysztof Misiukiewicz; Benjamin Greenbaum; Andres Salazar; Philip Friedlander; Nina Bhardwaj
Journal:  Clin Cancer Res       Date:  2018-06-27       Impact factor: 12.531

Review 2.  Complex interplay between tumor microenvironment and cancer therapy.

Authors:  Minhong Shen; Yibin Kang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

Review 3.  Dendritic cell-based immunotherapy.

Authors:  Rachel L Sabado; Sreekumar Balan; Nina Bhardwaj
Journal:  Cell Res       Date:  2016-12-27       Impact factor: 25.617

4.  Protocols to Manufacture an Oncolytic Measles Virus-Sensitive Immunocompetent Mouse Model of Medulloblastoma.

Authors:  Sangeet Lal; Corey Raffel
Journal:  Methods Mol Biol       Date:  2022

Review 5.  The Role of Oncolytic Viruses in the Treatment of Melanoma.

Authors:  Claire-Audrey Y Bayan; Adriana T Lopez; Robyn D Gartrell; Kimberly M Komatsubara; Margaret Bogardus; Nisha Rao; Cynthia Chen; Thomas D Hart; Thomas Enzler; Emanuelle M Rizk; Jaya Sarin Pradhan; Douglas K Marks; Larisa J Geskin; Yvonne M Saenger
Journal:  Curr Oncol Rep       Date:  2018-08-25       Impact factor: 5.075

Review 6.  SARS-COV-2 infection and lung tumor microenvironment.

Authors:  Naila Malkani; Muhammad Usman Rashid
Journal:  Mol Biol Rep       Date:  2021-01-23       Impact factor: 2.316

7.  Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.

Authors:  Yang Liu; Jing Cai; Wenfeng Liu; Yuan Lin; Li Guo; Xincheng Liu; Zhen Qin; Cuiying Xu; Yanming Zhang; Xingwen Su; Kai Deng; Guangmei Yan; Jiankai Liang
Journal:  Cell Death Dis       Date:  2020-12-12       Impact factor: 8.469

8.  Immunotherapeutic Potential of Oncolytic H-1 Parvovirus: Hints of Glioblastoma Microenvironment Conversion towards Immunogenicity.

Authors:  Assia L Angelova; Milena Barf; Karsten Geletneky; Andreas Unterberg; Jean Rommelaere
Journal:  Viruses       Date:  2017-12-15       Impact factor: 5.048

9.  Oncolytic virus synergizes with Smac mimetic compounds to induce rhabdomyosarcoma cell death in a syngeneic murine model.

Authors:  Christine C Dobson; Thet Naing; Shawn T Beug; Mame D Faye; Janelle Chabot; Martin St-Jean; Danielle E Walker; Eric C LaCasse; David F Stojdl; Robert G Korneluk; Martin Holcik
Journal:  Oncotarget       Date:  2017-01-10

10.  Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.

Authors:  Ifeanyi Kingsley Uche; Natalie Fowlkes; Luan Vu; Tatiane Watanabe; Mariano Carossino; Rafiq Nabi; Fabio Del Piero; Jared S Rudd; Konstantin G Kousoulas; Paul J F Rider
Journal:  J Virol       Date:  2021-01-13       Impact factor: 6.549
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.